Electronic Drug Delivery Systems Market Size, Share & Trends Analysis Report By Type (Wearable Infusion Pumps, Auto Injectors, Injection Pens, and Inhalers), By Application (Diabetes, Cardiovascular Disease (CVD), Respiratory Disorders, Multiple Sclerosis ), By Distribution Channel, By Region, And Segment Forecasts, 2024-2031
The Global Electronic Drug Delivery Systems Market Size is valued at 11.02 billion in 2023 and is predicted to reach 18.81 billion by the year 2031 at a 7.06% CAGR during the forecast period for 2024-2031.
Electronic drug delivery systems, or "smart drug delivery devices," are particularly well adapted to home care settings. These developments increase the value of obsolete tools, which also increases their usefulness and applicability. The rise in the incidence of target diseases is the main factor causing the market for electronic drug delivery systems to expand quickly.
In addition, favorable reimbursement policies in essential markets, rapid technological and design developments, a rise in the incidence of chronic diseases, and a rise in the number of elderly patients are all anticipated to contribute to the growth of the demand for electronic drug delivery systems.
The market for electronic drug delivery systems is constrained by high initial R&D expenditures and strict regulations, whereas the unfavorable reimbursement structure in emerging nations will impede market expansion.
Moreover, the market for electronic drug delivery systems will have plenty of growth prospects due to rising healthcare costs and strong demand for biologics and mAbs.
Recent Developments:
- In April 2022, Halozyme Therapeutics, Inc. and Antares Pharma, Inc. announced that they would sign a contract under which Halozyme would buy Antares for USD 5.60 in cash per share. The acquisition, which values Antares at around USD 960 million, was approved by the boards of directors of Halozyme and Antares unanimously. A market-leading specialized product and drug delivery company will be created due to Halozyme and Antares' merger.
- In August 2019, the successful acquisition of BlueRock Therapeutics for USD 1 billion was announced by Bayer AG. The company works in the field of regenerative medicine.
Competitive Landscape:
Some of the major key players in the electronic drug delivery systems market are:
- Bayer AG
- Gerresheimer AG
- Medtronic
- Elcam Medical
- Novo Nordisk A/S
- Insulet Corporation
- BD
- Sanofi
- Frederick Furness Publishing
- United Therapeutics Corporation
- AstraZeneca
- Tandem Diabetes Care
- Merck Group Amgen
- United Therapeutics Corporation
- Hoffmann-La Roche
- Companion Medical
Market Segmentation:
The electronic drug delivery systems market is segmented based on type, application and distribution channel. Based on type, the market is segregated as Wearable Infusion Pumps, Auto Injectors, Injection Pens and Inhalers. By application, the market is segmented into Diabetes, Cardiovascular Disease (CVD), Respiratory Disorders, Multiple Sclerosis and Others. Based on type, the market is segregated into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies.
By Type, The Market For Electronic Drug Delivery Systems Is Significantly Impacted By The Wearable Infusion Pump Segment
The wearable infusion pumps category is expected to hold a major share in the global electronic drug delivery systems market in 2024. This is a result of the device's growing use in the effective management of chronic diseases like diabetes. Patients are less likely to use traditional pumps since they are more expensive and challenging to use. Recent smaller wearable pumps that provide equivalent health results to conventional therapy have promoted changes in patient behavior.
Online Pharmacies Segment Witnessed Growth At A Rapid Rate
The online pharmacies segment is projected to grow at a rapid rate in the global electronic drug delivery systems market. This results from more people using easy-to-use online pharmacies to buy prescription drugs. Given the importance of the internet in our lives, the move of pharmacies to an online platform was not unexpected. Studies show that ordering prescription drugs online can save consumers up to one-third of their overall costs. Patients gain a lot from e-pharmacy because it offers more options than a traditional pharmacy.
The North America Electronic Drug Delivery Systems Market Holds A Significant Revenue Share In The Region
Electronic drug delivery systems are used to treat diabetes and epilepsy and are increasingly used to treat a variety of chronic conditions, including diabetes. As a result, the North American market for electronic drug delivery systems is expected to record the highest market share in terms of revenue in the near future. In addition, the efforts of numerous manufacturers to develop intelligent solutions that can be tailored to the patient's experience are driving market revenue growth.
In addition, the Asia Pacific region is anticipated to grow swiftly in the global market for electronic drug delivery systems. This is due to the prevalence of chronic diseases such as diabetes, the increasing demand for sophisticated drug delivery platforms, and increased efforts to produce biosimilars. For example, the prevalence of type 2 diabetes has grown significantly in Asia and China over the past few decades, despite the fact that the global incidence of diabetes has increased over the same time period.
Electronic Drug Delivery Systems Market Report Scope:
| Report Attribute | Specifications |
| Market size value in 2023 | USD 11.02 Bn |
| Revenue forecast in 2031 | USD 18.81 Bn |
| Growth rate CAGR | CAGR of 7.06% from 2024 to 2031 |
| Quantitative units | Representation of revenue in US$ Billion, volume (units) and CAGR from 2024 to 2031 |
| Historic Year | 2019 to 2023 |
| Forecast Year | 2024-2031 |
| Report coverage | The forecast of revenue, the position of the company, the competitive market statistics, growth prospects, and trends |
| Segments covered | Type, Application And Distribution Channel |
| Regional scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; Southeast Asia |
| Competitive Landscape | Bayer AG, Gerresheimer AG, Medtronic, Elcam Medical, Novo Nordisk A/S, Insulet Corporation, Becton and Dickinson Company (BD), Sanofi and Frederick Furness Publishing. |
| Customization scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing and available payment methods | Explore pricing alternatives that are customized to your particular study requirements. |
Segmentation of Electronic Drug Delivery Systems Market-
Electronic Drug Delivery Systems Market By Type
- Wearable Infusion Pumps
- Auto Injectors
- Injection Pens
- Inhalers
Electronic Drug Delivery Systems Market By Application
- Diabetes
- Cardiovascular Disease (CVD)
- Respiratory Disorders
- Multiple Sclerosis
- Others
Electronic Drug Delivery Systems Market By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Electronic Drug Delivery Systems Market By Region-
North America-
- The US
- Canada
- Mexico
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- South East Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Argentina
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of Middle East and Africa
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
Electronic Drug Delivery Systems Market Size is valued at 11.02 billion in 2023 and is predicted to reach 18.81 billion by the year 2031
Electronic Drug Delivery Systems Market expected to grow at a 7.06% CAGR during the forecast period for 2024-2031
Bayer AG, Gerresheimer AG, Medtronic, Elcam Medical, Novo Nordisk A/S, Insulet Corporation, Becton and Dickinson Company (BD)